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Abstract
The half maximal inhibitory concentration (IC50) has several limitations that make it unsuitable
for examining a large number of compounds in cytotoxicity studies, particularly when multiple
exposure periods are tested. This article proposes a new approach to measure drug effectiveness,
which allows ranking compounds according to their toxic effects on live cells. This effectiveness
measure, which combines all exposure times tested, compares the growth rates of a particular cell
line in the presence of the compound with its growth rate in the presence of DMSO alone. Our
approach allows measuring a wider spectrum of toxicity than the IC50 approach, and allows
automatic analyses of a large number of compounds. It can be easily implemented in linear
regression software, provides a comparable measure of effectiveness for each investigated
compound (both toxic and non-toxic), and allows statistically testing the null hypothesis that a
compound is non-toxic versus the alternative that it is toxic. Importantly, our approach allows
defining an automated decision rule for deciding whether a compound is significantly toxic. As an
illustration, we describe the results of a cell-based study of the cytotoxicity of 24 analogs of
novobiocin, a C-terminal inhibitor of heat shock protein 90 (Hsp90); the compounds were ranked
in order of cytotoxicity to a panel of 18 cancer cell lines and 1 normal cell line. Our approach may
also be a good alternative to computing the half maximal effective concentration (EC50) in studies
searching for compounds that promote cell growth.
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INTRODUCTION
The half maximal inhibitory concentration (IC50) is used to assess and compare the
effectiveness of inhibitory compounds. In particular, it has been regularly used to investigate
the toxicity of compounds in cell-based assays, e.g. assays searching for novel anticancer
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drugs. However, the mechanism of action of a toxin is not analogous to the simple receptor-
ligand-interaction mechanism that usually justifies using the IC50. In fact, the IC50 has some
limitations that make it unsuitable for the simultaneous examination of a large number of
compounds in high throughput screening (HTS) settings. These limitations stem from the
inappropriate application of IC50 to assays and situations that were not originally intended
for the IC50 calculation. The limitations of the IC50 in HTS situations are: (1) it requires a
well shaped dose response curve, (2) it requires a wide range of concentrations of antagonist
tested, (3) IC50 measurements cannot be directly compared across assays with different time
frames of antagonist exposure, and (4) IC50 measurements cannot be used to statistically test
the null hypothesis that a compound is not toxic. The purpose of this article is to propose a
new measure of compound effectiveness that overcomes these limitations when two or more
exposure times are examined for each compound in a cell-based HTS setting.
Next we discuss the practical impact of the above limitations on HTS. Since the IC50 can be
reliably computed only when the cell-growth-inhibition versus compound concentration
curve has reached a plateau, its computation requires a previous visual inspection of this
curve for each compound; as a consequence of this, an automatic computation of the IC50 is
usually difficult and, especially when dealing with a large number of compounds, human
errors are bound to happen and the comparison of compounds is very time-consuming. Also,
with the low concentrations that are usually tested in HTS, it is common that many curves
do not reach a clear plateau. In the absence of a sigmoidal relationship of compound
concentration to response, no reliable IC50 measurement can be obtained. Consequently, the
IC50 concept is limited in its ability to provide tools for comparing compounds tested in
HTS on a quantitative basis.
The IC50 is time-dependent, that is, its value and the possibility of computing it depend on
the duration of the exposure of the cells to the compound. This is not a shortcoming by itself
if all investigated compounds are tested on the same exposure time and an IC50 for all
compounds is available. However, this does create complications for the statistical analysis
of data from screens that test the toxicity of the same compounds for two or more exposure
times. In particular, it is unclear how to compute a unified measure of compound
effectiveness that combines the available IC50’s from different exposure periods. A
commonly adopted practical solution is to use only one exposure time in compound
comparisons. Unfortunately, ignoring the information from other available exposure times is
clearly an insufficient evaluation of efficacy and excludes the possibility of computing a
more precise measure of effectiveness that combines all the available information.
Numerous examples from literature provide evidence that the exposure time of a compound
has a direct effect on IC50 measurements [1–2]. The ability to analyze the effects exerted by
a compound at a given concentration over a series of time points can provide invaluable
information for the optimal concentration for efficacy and duration of action. Obtaining this
information as early as possible during the drug discovery and development process is
economically ideal and affords preliminary insight into the pharmacokinetic and
pharmacodynamic properties of a given compound.
In cell-based HTS settings, there is a need for statistical methods that allow testing the null
hypothesis that a compound is not toxic versus the alternative hypothesis that it is. A
limitation of the IC50 approach to measuring cytotoxicity is that it cannot be used to
implement methods of testing this null hypothesis. The reason is that the IC50 concept is
undefined for non-toxic compounds, which implies that any IC50 measurement is computed
under the assumption that the compound is toxic. Consequently, an acceptance region for the
null hypothesis cannot be defined by using a test statistic based on IC50 measurements, and
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automated decision rules that allow deciding whether a compound is significantly toxic
cannot be designed by using IC50 measurements.
Another method that is used to measure drug effectiveness is the area under the curve. This
method quantifies the area under the dose-response curve of compound effectiveness, e.g.
inhibitor versus compound concentration. Although this area is always computable and can
be computed automatically (at least when using a trapezoidal rule), even when no plateau on
the curve is observed, the fact that this measure is also time-dependent causes analogous
difficulties to those described above for computing IC50 values when two or more exposure
times are examined.
The approach proposed in this article possesses none of the disadvantages mentioned above
for the IC50 or the area under the curve. In particular, our approach provides a measure of
effectiveness that combines all exposure times tested, allowing the automatic computation of
the effectiveness of a large number of compounds. This new method can be easily
implemented in linear regression software, provides a comparable measure of effectiveness
for each investigated compound, and allows testing the null hypothesis that a compound is
non-toxic versus the alternative that it is toxic. We describe herein empirical evidence that
suggests that our approach provides measures of effectiveness that highly correlate with
IC50 measurements when the latter are available. Thus, our approach seems to retain the best
features of the IC50 approach while overcoming some of its observed disadvantages in HTS
analyses involving multiple times. As described in the Discussion Section, our approach can
also be a good alternative to the half maximal effective concentration (EC50) in HTS
investigations searching for compounds that promote cell growth; this additional application
only requires a slight modification to the interpretation of our measure of effectiveness.
To illustrate the proposed methodology, we describe the results of an HTS study of the
cytotoxicity of 24 rationally-designed analogs of novobiocin, a C-terminal inhibitor of heat
shock protein 90 (Hsp90). The goal of this cell-based assay was to rank each of the 24
compounds in order of cytotoxicity to a panel of 18 cancer cell lines and 1 normal cell line.
Chaperone heat shock proteins play crucial roles in protein folding, assembly of multiprotein
complexes, transport of proteins into correct subcellular compartments, cell-cycle control
and signaling, and the protection of cells against stress/apoptosis [3–4]. Hsp90 is a potential
therapeutic target for anticancer therapy as it regulates the activity of over 200 client
proteins, impacting numerous cellular pathways in both normal and cancer cells [4–7].
Drugs that specifically block Hsp90 function contain antitumor activity, and many Hsp90
client proteins are kinases involved in cell proliferation, making Hsp90 an ideal target for
anticancer therapeutics. Inhibition of Hsp90 leads to depletion of client proteins involved in
the major hallmarks of cancer, including evading apoptosis and detection by the immune
system, angiogenesis, invasion and metastasis [7]. In addition, increased Hsp90 expression
is observed in cancerous cells in attempts to maintain homeostasis in the hostile environment
caused by neoplastic transformation. This upregulation provides a degree of selectivity over
non-cancerous cells and could reduce toxicity by selectively inhibiting the progression of
cancer-associated Hsp90. The power of specific Hsp90 inhibitors rests with their ability to
simultaneously disrupt multiple oncogenic signaling pathways [5, 8]. Clinical trials with
current Hsp90 inhibitors have been hampered by limited efficacy and moderate systemic
toxicity unrelated to Hsp90 inhibition. The analogs of novobiocin that are examined in this
article were synthesized with the purpose of developing more potent and specific inhibitors
of Hsp90 for use in developing anticancer chemotherapeutics [9–13].
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The investigated compounds are listed in the first column of Table 2. Twenty-four of these
compounds (named with a KU prefix) were synthesized at the University of Kansas; 17-
AAG and novobiocin were also examined as a standard for Hsp90 inhibition. The cytotoxic
effects of these compounds on 19 cell lines were studied. The cell lines are described in
Table 1. A schematic diagram of our overall approach is summarized in Fig. (1).
Cell Viability Assays
Cell viability after exposure to a specific concentration of a compound was assessed using
the CellTiter-Glo homogenous luminescent cell viability assay (Promega Co., Madison,
WI). Cells exposed to the compound were incubated at 37 °C and 5% CO2 in a 95%
humidified incubator. Four different exposure durations were implemented (4, 24, 48, or 72
hours). After incubation, the cells were removed from the incubator and left at room
temperature for 20 minutes to equilibrate the plate and its contents to room temperature.
CellTiter-Glo reagent was added to the cells, at 10 μL per well, and plates were shaken for
two minutes at room temperature and 1600 rpm (250 rcf) speed. Fifteen minutes later, plate
luminescence was read on the PerkinElmer Envision to quantitate cell viability. The
luminescence values used for data analysis reflected the number of viable cells. Viability
was detected by quantitation of the ATP present, which confirms the presence of
metabolically active cells. The CellTiter-Glo reagent acts by lysing cells and generating a
luminescent signal proportional to the amount of ATP present, and therefore proportional to
the number of cells present. The luciferase reaction was based on mono-oxygenation of
luciferin, catalyzed by luciferase in the presence of Mg2+, ATP and molecular oxygen.
Compound Plate Preparation
Compounds were received at 10 mM in 50 μL of 100% dimethyl sulfoxide (DMSO). They
were diluted to 6 mM (100% DMSO) and placed in columns 3 and 13 of 384-well
polypropylene plates (83.3 μL of each 6 mM compound). Serial dilutions were performed
(in 100% DMSO) for compounds in column 3 across to column 12, and compounds in
column 13 were diluted across to column 22. The serial dilutions were performed by
transferring 33.3 μL from each well to receiving well containing 50 μL DMSO. After
mixing, 33.3 μL were transferred to the next well containing 50 μL DMSO and so on. The
final volume in each well was 50 μL. For each of the investigated compounds, 10 different
compound concentrations were tested on the cells: 30.0 μM, 18.0 μM, 10.8 μM, 6.5 μM, 3.9
μM, 2.3 μM, 1.4 μM, 0.840 μM, 0.504 μM, and 0.302 μM. For each of the 19 cell lines, cell
growth curves were used to determine how many initial cells to seed per well of each plate.
A total of 4 plates were used for each cell line. Each plate corresponded to 1 of the 4
compound-exposure durations (4, 24, 48 or 72 hours), allowed testing for 10 different
concentrations of each of the investigated compounds and also allowed testing of the DMSO
vehicle alone.
Statistical Model of Luminescence Measures
For a particular compound and cell line, the following notation will be used: T = time at
which luminescence is measured (in the Hsp90 study, T = 4, 24, 48 or 72 hours; initial
seeding occurs at T = 0); N = number of cells in a well at a particular time T; L = measured
luminescence when there are N cells in the well; N0 = number of cells initially seeded in the
well; L0 = luminescence corresponding to N0 cells (not measured in the Hsp90 study); and λ
= growth rate per cell of the cell population (dependent on compound dose).
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The exponential cell growth model was used to describe cell proliferation [14]. According to
this model, ; thus, N = N0 exp(λT). This is the standard model of population size
when conditions are kept constant and the population has sufficient availability of resources
such as nutrients and water over the observation time period.
Our approach to measure drug effectiveness assumes that there is a proportional relationship
between luminescence and the number of cells in the well. The manufacturer’s report for the
CellTiter-Glo luminescent assay provides evidence of this proportional relationship [15],
and we confirmed this relationship in our lab by testing MCF-7 cells using a range of 4–
125,000 cells per well. The proportionality assumption states that L = kN, where k is a
proportionality constant. Thus, by the exponential growth model and this assumption, for a
particular compound concentration and cell line,
This implies that
(1)
where log(L) is the natural logarithm of L. It is important to note that log(L0) is unknown but
constant across all assays corresponding to a particular cell line, because the initial number
of cells, N0 was the same for all compounds and concentrations tested. (Since luminescence
was proportional to the amount of viable cells in the well, we did not expect that log(L0) was
affected by sample concentration). For a particular compound, let Ci, i = 1, …, n, denote the
n different concentrations tested on the cell line (in the Hsp90 study, n =10). It is assumed
that these n concentrations were used for all investigated compounds. Each of these
concentrations contributes to an equation like equation (1), where λ depends on the
particular compound concentration tested.
Thus, for a particular cell line and compound d, the luminescence measures can be modeled
with the following set of n +1 equations:
(2)
where λd,i is the growth rate per cell of the investigated cell line in the presence of
compound d at concentration Ci, i =1, …, n; and λ0 is its growth rate in the presence of only
DMSO vehicle (compound concentration=0).
After combining the above n +1 equations, and since log(L0) is the same in all n +1
equations, we obtain the following linear regression model of an individual luminescence
measure L from a particular combination of compound and cell line:
(3)
where X0 =1 if the cells in the well were exposed to DMSO alone, and X0 =0 otherwise; and
Xi =1 if the cells were exposed to compound d at concentration Ci, and Xi =0 if the cells
were exposed to a compound concentration other than Ci or to DMSO alone, i =1, …, n.
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Observe that the growth rates λd,i and λ0 in model (3) are regression coefficients, and
log(L0) can be estimated as an intercept. To see why equation (3) represents all n +1
equations in (2), observe that, for instance, if L is a particular luminescence measure from a
well that contained cells exposed to compound concentration C1 during T units of time, then
X1 =1 and Xi =0 for all i ≠1. Entering these numbers into equation (3), we obtain that
which is the equation corresponding to concentration C1 in (2). Analogous arguments can be
used to obtain the other equations in (2) from (3).
Observe that, to be able to fit model (3) with standard linear regression software to data from
one particular combination of compound and cell line, the database must initially contain n
+3 columns (“variables”), and each row in the database must contain information
corresponding to only one luminescence measure, that is, information from only one well.
Specifically, one column must contain all the luminescence measures L obtained from the
particular combination of compound and cell line; another column must contain the times T
at which the corresponding luminescence measures were obtained; and the remaining n +1
columns must contain the values of X0, X1, …, Xn. For a particular row in the database, only
one entry of these latter n +1 columns should have a value of 1, and the other entries of the n
+1 columns should be 0, because each well is treated with one and only one compound
concentration. Once this database is in place, additional columns TX0, TX1, …, TXn, and
log(L) need to be calculated. The columns TX0, TX1, …, TXn are the independent variables
of model (3), whereas log(L) is the dependent variable.
Effectiveness Measure
The effectiveness of compound d at concentration Ci was defined as
(4)
where r is the longest time at which luminescence was measured (in the Hsp90 study, r =72
hours). If r is measured in hours, Ed,i is interpreted as the proportion of cells killed by
compound d at concentration Ci after r hours of exposure to the compound. This
interpretation is justified by the equation
That is, Ed,i compares the number of surviving cells after r units of time of uncontrolled
growth (i.e. under DMSO alone) with the number of cells that survived after r units of time
of compound exposure, regardless of the initial number of cells.
The overall effectiveness εd of a compound d was defined as the area under the curve for the
plot of Ed,i versus Ci, computed with the trapezoidal rule (Fig. 2); that is:
(5)
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where C0 =0. A positive value of εd indicates compound toxicity and a negative value of εd
indicates that the compound favors cell growth.
Model Fit
For a particular combination of compound and cell line investigated in the Hsp90 study, the
values of the covariates TXi, i =0, 1, …, 10, were computed for each well of the 4 plates. (A
well contained cells treated with a particular concentration of compound, or contained cells
in DMSO alone; moreover, each well has an associated exposure time T). These covariates
and their corresponding luminescence measures were used to fit the linear regression model
(3) using Stata [16].
For each cell line, before fitting the regression models, the adequacy of the exponential
growth model was examined by plotting the log of luminescence versus time using all the
DMSO-only data from that cell line. This growth model predicts that the plotted points
should follow a linear relationship (Fig. 3). Although only 4 time points were available, a
linear relationship was observed for 13 of the 19 cell lines. For these cell lines, all available
information was used to fit the regression models. For 5 of the 6 cell lines that did not
exhibit a linear relationship (HT-1376, Jurkat, MRC-5, NCI-H226 and SK-BR-3), linearity
was obtained by excluding the DMSO-only data corresponding to one of the 4 time points.
For instance, for MRC-5, a linear relationship was obtained after excluding the 72-hours
exposure DMSO data. In order to obtain a reliable estimator of λ 0, which is the reference
growth rate, the regression models for these 5 cell lines were fitted by using only the
DMSO-only data corresponding to the 3 time points that yielded the linearity, plus all
compound-exposure data. One cell line, Coav-3, did not exhibit any obvious linearity in the
relationship between the log of luminescence and time, not even after leaving only 3 time
points. For Coav-3, however, regression models were fitted using all the available
information.
Each combination of compound and cell line provided a total of 96 luminescence measures
(10 for compound exposures and 14 for DMSO-only exposures from each of the four
different exposure durations). Thus, for the 5 cell lines for which one time point from
DMSO data was excluded, the design matrix of the regression model contained a total of 82
rows. For the remaining 14 cell lines, it contained 96 rows.
To test the null hypothesis H0: εd ≤ 0 (the compound is non-toxic) versus the alternative H1:
εd >0 (the compound is toxic), a 1-tailed t-test was used. Since εd is a nonlinear contrast of
the regression coefficients of model (3), the delta method was used to compute its standard
error [17]. Stata’s nlcom command was used for these computations. For each cell line, p-
values from t-tests were corrected to account for multiple comparisons. Simes’ method was
used for these corrections, which controls the false discovery rate [18]; the method started
with an uncorrected overall critical p-value of 0.05.
IC50 Assessments
For comparison purposes, independent measures of IC50’s were obtained by using the data
corresponding to a 72-hour exposure (Table 3). For reasons similar to those described in the
introduction, it was not possible to obtain reliable IC50 measurements for all compounds or
all cell lines. Only reliable measurements are reported in Table 3. The chemist who obtained
IC50 measurements had substantial prior experience computing IC50 measurements and was
not aware of the model or its results at the time of IC50 computations. Also, model
development and effectiveness computations were done without knowledge of results from
IC50 computations. For each cell line that provided IC50 measurements, a Spearman’s
correlation across compounds between available IC50’s and their corresponding εd’s was
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computed (last row of Table 3). Similarly, for each compound that provided IC50
measurements, a Spearman’s correlation across cell lines was computed (last column of
Table 3). Correlation coefficients were reported only if there were 3 or more pairs (IC50,
overall effectiveness) available.
Assessment of the Goodness-of-the-Fit of the Linear Model
For each combination of compound and cell line, the goodness-of-the-fit of linear regression
model (3) was assessed through the correlation coefficient between the predicted and
observed log-transformed luminescence measures; this correlation is given by the square
root of the usual coefficient of determination R2. For each combination of compound and
cell line, a correlation coefficient was computed (Table 4).
RESULTS
For each cell line, Table 2 shows the values of overall effectiveness εd for the investigated
compounds. Overall effectivenesses that were significantly greater than 0, which indicates a
statistically significant toxicity, are highlighted. For instance, the overall effectiveness of
compound KU-174 for killing A549 cells was εd = 1921.3 (13th column, 2nd row of the
table); this effectiveness was significantly greater than 0. In contrast, the overall
effectiveness of compound KU-124 for killing A549 cells was positive but not significantly
greater than 0 (εd = 376.7).
The rows in Table 2 are sorted from highest to lowest compound toxicity (up to down). To
sort the rows, all εd’s for each compound d were added up across columns. Then the rows
were sorted from the highest to the lowest value of this sum. Similarly, the columns in Table
2 are sorted from highest to lowest cell line’s sensitivity (left to right), by using the sums of
εd’s across rows (the higher the sum the more sensitive the cell line was to the set of tested
compounds).
Table 2 shows that KU-174, 17-AAG and KU-135 were the most toxic compounds, and that
Novobiocin was the least toxic. In fact, novobiocin was toxic to only the normal cell line,
MRC-5 (εd = 783.6).
Comparisons with Available IC50 Measurements
All correlation coefficients between available IC50’s and effectiveness measurements εd
were negative, and most were substantially high in absolute value (Table 3). For instance,
for the Jurkat cell line, r=−0.82 (p<0.001, N=15; last row of Table 3), and for the KU-135
compound, r=−0.93 (p=0.001, N=8; last column of Table 3). Eight out of nine within-cell
correlations were both ≤ −0.7 and significantly different from 0 (last row of Table 3).
Similarly, eight out of 11 within-compound correlations were ≤ − 0.7, although only 5 of
these were significant (last column of Table 3). The significant within-compound
correlations were those computed with sample sizes ≥ 7, whereas the non-significant within-
compound correlations were computed with sample sizes <7; this suggests that the non-
significant p-values in the last column of Table 3 may be due to a lack of statistical power
determined by sample sizes that were not sufficiently large.
The correlations reported in Table 3 suggest that εd may convey the same information as the
IC50 does when the latter is available. In fact, the negative correlations in Table 3
demonstrate that compounds with experimentally derived low IC50 values (an indication of
toxicity at low concentrations) tend to have high εd values, which supports our view that εd
can be interpreted as a measure of compound toxicity. However, the IC50 could not be
measured in many instances where the compound was significantly toxic according to the
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overall effectiveness εd (Table 3), suggesting that focusing on computing only the IC50 in
HTS analyses may lead to loss of information.
Table 3 also shows that IC50’s tended to be available only for compounds that had large
values of εd. In fact, a negative or relatively low effectiveness εd was correlated with the
inability to measure the IC50 under the tested concentrations. An extreme situation occurred
for the MCR-5 cell line, where the IC50 was computable only for the compound with the
highest toxicity according to our approach (17-AAG; Table 3). Thus, our approach not only
reflects the information that is usually provided by the IC50, but is also able to measure a
wider spectrum of toxicity.
GOODNESS OF THE FIT OF THE LINEAR MODEL
Table 4 describes the correlation coefficients between observed and predicted log-
transformed luminescence measures, where the predictions were provided by model (3).
Each row in Table 4 shows the minimum, maximum and average correlation of a set of 26
correlations corresponding to the 26 investigated compounds. For most cell lines, model (3)
fit remarkably well. In fact, for 13 out of the 19 cell lines, the correlations between observed
and predicted log-luminescence measures were of at least 0.80 across the 26 investigated
compounds (Table 4). Some of the investigated cell lines (LNCap and HT-29) exhibited an
almost perfect model goodness-of-fit for each of the 26 compounds, with an average
correlation of 0.99 and minimum correlations not lower than 0.93.
The lowest (across cell lines) average correlation was 0.60 (Table 4), which still can be
considered as indicating a model with reasonably good predictive capabilities, at least from
a practical point of view. The poorest model fits were observed from the 26 regressions for
the Coav-3 cell line (Table 4), which is not surprising because initial graphical analyses
showed that for this cell line there did not seem to be linearity in the relationship between
log-transformed luminescence and time under DMSO alone. The minimum and average
correlations for the Coav-3 cell line (0.53 and 0.60, respectively) were the lowest among all
investigated cell lines, although compounds producing correlations of up to 0.85 were
observed for Coav-3.
The strong evidence of goodness-of-fit in Table 4, and the high correlations between the
IC50 and our measure of overall compound effectiveness in Table 3, provide evidence that
our linear model has good predictive capabilities and strongly support the usefulness of our
model as a tool in HTS studies.
DISCUSSION
This article describes a statistical methodology for ranking compounds according to their
toxic effects on live cells. Our approach is theoretically sound, since it makes use of a well
established model in mathematical biology, the exponential growth model [14], and of
known quantitative properties of a luminescent assay [15]. Our approach computes a
measure of compound effectiveness that essentially compares the growth rates of a
particular cell line in the presence of the compound with its growth rate in the presence of
only DMSO. We found compelling evidence that the exponential growth model is applicable
in an HTS setting, by using luminescence measurements obtained after cell exposure to
DMSO alone (Fig. 3). Unfortunately, the adequacy of the exponential growth model could
not be directly examined by plotting data from cells exposed to the investigated compounds,
because only 4 observations per investigated compound concentration were available.
However, we were able to examine the goodness-of-the-fit of a linear model that is implied
by the exponential growth model, namely model (3), by examining the correlations between
predicted and observed log-transformed luminescences. The linear model fit relatively well
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in most of the investigated cell lines (Table 4). Our computations of overall compound
effectiveness relied on this linear model. A similar measure of compound effectiveness to
that in formula (4) was successfully used to investigate the effects of mechanical forces on
the efficacy of anti-lung cancer drugs [19].
We investigated the performance of our approach by using data from an HTS study of the
toxic effects of a family of compounds on 19 cell lines, of which 18 were cancerous. We
found that the proposed approach enhanced our ability to measure the toxicity of the
investigated compounds, allowing us to measure a wider range of cytotoxicity than the range
allowed by the IC50 approach. In particular, our approach seems to be more suitable for
comparing compounds with low levels of toxicity since, in this class of compounds, the IC50
approach may not produce any reliable number if low dosages are tested in the experiments.
An advantage of the proposed approach is that it combines all available information —
durations of exposure to the compound, compound concentrations, and luminescence
measurements for cells that were in the presence of the compound versus vehicle DMSO—
in only one measure of toxicity, εd. In particular, the use of luminescence measures in the
presence of DMSO vehicle alone allows considering εd. as a standardized measure of
toxicity. Another advantage of our approach over the IC50 approach is that a statistical test
of the null hypothesis that the compound is not toxic (εd ≤ 0) can be performed. In fact, such
a test cannot be performed by using IC50’s because, strictly speaking, the IC50 is defined
only for toxic compounds; in other words, any IC50 measure assumes that the compound has
some level of toxicity. An εd measure, in contrast, does not assume that the investigated
compound has any level of toxicity. Finally, our approach can easily be implemented in
linear regression software and is more suitable for automation. The latter characteristic is a
great advantage, especially in HTS analyses examining thousands of compounds.
We found that our proposed approach produces a measure of effectiveness that highly
correlates with IC50 measures in cases in which the latter are obtainable. Remarkably, this
correlation was high for the Coav-3 cell line (r=−0.89, p=0.02, N=6; last row of Table 3),
which provided DMSO-only data that did not seem to favor the exponential growth model.
The correlation was also high for the Jurkat cell line (r=−0.83, p=0.001, N=15), for which
we eliminated the DMSO-only data obtained at 24 hours before fitting the regression
models. Even more, for the Jurkat cell line the compounds with missing IC50 measurements
in Table 3 corresponded to those that had negative or small εd values in the corresponding
column in Table 2. These high correlations under rather unfavorable or “doubtful”
conditions suggest the robustness of our approach.
For 4 of the 5 cell lines for which one time point was excluded from the DMSO-only data in
order to achieve visual linearity in the relationship between log-transformed luminescence
and time under only DMSO, the average correlation measuring goodness of fit was
substantially high (HT-1376, average =0.88; Jurkat, 0.90; SK-BR-3, 0.86; and NCI-H226,
0.93; Table 4). Interestingly, for these cell lines, each regression model was fitted by using
42 luminescence measures under DMSO alone, plus 40 measures under compound
concentrations greater than 0. This means that these latter luminescence measures were quite
consistent with the exponential growth model. Moreover, Table 3 shows that, for the
HT-1376 and Jurkat cell lines, the correlations between available IC50 measures and overall
compound effectivenesses were high (−0.8 and −0.83, respectively). These facts suggest that
an initial preparation of DMSO-only data in order to make these data consistent with the
assumption of cell exponential growth may produce useful results, and that a seemingly lack
of conformity to the exponential growth model may perhaps be owing to some experimental
artifacts that may not consistently occur at all exposure durations, and may not be owing to a
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lack of biological conformity of cells to the exponential growth model under HTS
conditions.
A limitation of our approach is that it is not applicable when only one exposure duration has
been implemented in the HTS experiments. The reason for this is that the luminescence L0
corresponding to the initial number of cells N0 is not usually available. (This is also the
reason why the intercept log(L0) in model (3) needs to be estimated). In contrast, when there
is only one exposure duration, the area under the inhibition versus concentration curve can
always be computed with the trapezoidal rule; the IC50 can or cannot be computed,
depending on whether or not a clear plateau in this curve is reached.
Our approach also allows measuring “negative” toxicities (i.e. εd <0), which reflect that a
compound favors cell growth. It is likely that εd is a better, alternative measure to the EC50,
which is typically used in cell-based HTS explorations focused on finding compounds that
stimulate cell growth. In fact, EC50’s essentially have the same limitations as IC50’s. In
those explorations, a low negative value of εd can be interpreted as reflecting a high
efficacy, and a minor modification of the statistical test described in the Methods Section
can easily be carried out in order to test the null hypothesis of lack of compound efficacy (εd
≥ 0) versus the alternative of efficacy (εd <0).
Standard linear regression software usually applies ordinary least squares (OLS) by default
in order to estimate the regression coefficients of a linear regression model. In the context of
model (3), this estimation procedure will assume that the variance of the error is the same
across all different concentrations tested, and that the error is normal. Checking the
assumptions of constant variance (homoscedasticity) and normality after fitting a linear
regression model by exploring the model’s residuals is a routine statistical practice.
However, residuals explorations usually involve visual analyses of plots that are not easy to
automate in computer platforms and, therefore, do not seem to be applicable in HTS
campaigns fitting hundreds or thousands of regression models. Although statistical tests of
homoscedasticity or normality are available and are amenable to automation, experienced
statisticians know that these tests cannot be performed in isolation, that is, without additional
residual analyses, because such tests can produce significant p-values in the presence of
negligible deviations from the assumptions when the sample size is sufficiently large.
However, it is a well known and fortunate fact that OLS estimators are fairly robust to
deviations from the constant variance or normality assumptions, especially with sufficiently
large samples [20, 21]. Even more, under very general conditions, OLS estimators are
consistent and asymptotically normal, even in the absence of homoscedasticity or in the
presence of non-normal errors [20]. These conditions, along with some additional technical
conditions that are satisfied by equation (5), also guarantee the asymptotic normality of εd
[17, 20], which is in the core of the statistical test that we used to examine the significance
of εd. (The above technical conditions are stated in the mathematical result called “delta
method” [20]). Therefore, the normality or homoscedasticity of the errors in model (3) is not
a necessary condition for the applicability of our statistical test.
Nonetheless, if major deviations from standard OLS assumptions are suspected, the
regression coefficients in model (3) can still be estimated through robust linear regression
methods, which are implemented in some statistical packages. However, these methods
usually have less statistical power than OLS when the general conditions for the asymptotic
normality of OLS estimators are satisfied, which include many situations without
homoscedasticity or normality. As a rule of thumb, we recommend that robust methods be
used only when an unavoidable presence of many outliers across compounds is suspected.
Also, it is a good practice to conduct a visual inspection of residuals for the models
corresponding to those effective compounds that are selected for future experimental
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investigations, especially if their models show small R values. A visual inspection of the
residuals of randomly selected models is also recommendable in order to identify potential
estimation problems in the entire HTS campaign. In our study, residual analyses did not
indicate evidence of serious departures from normality or homoscedasticity, except perhaps
for the models corresponding to the OVCAR3 cell line. This is not totally unexpected
because the OVCAR3 models had on average the lowest R values (Table 4).
As another application, model (3) can be used to examine the significance of the
effectiveness of a particular compound concentration. For each concentration Ci, the null
hypothesis of non-toxicity H 0: Ed,i ≤ 0 versus the alternative H1: Ed,i >0 can be tested by
using a 1-tailed t-test. Since Ed,i >0 if and only if λ0 − λd,i >0, the t-test statistic:
can be used, where λ̂0 and λ̂d,i are the estimators of λ0 and λd,i, respectively; and se(λ̂0 − λ̂d,i
is the standard error of λ̂0 − λ̂d,i, obtained when the parameters in regression model (3) are
estimated. We reject the null hypothesis H0 when the p-value P(T >t) is <0.05, where T is a t
random variable with appropriate degrees of freedom. Interestingly, observe that, although
Ed,i is time dependent, the above statistical test is not because t is a function of only the
estimators of the growth rates λ0 and λd,i. Provided that the plate wells have sufficient
resources for the cells during the experiment, these growth rates should not be substantially
affected by experiment durations.
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Schematic diagram of assay approach to determine εd values for the 24 KU compounds, 17-
AAG and novobiocin. DMSO control was also tested.
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Schematic representation of the computation of the overall effectiveness εd of a particular
compound d, assuming that n =5 compound concentrations were used in HTS experiments.
The overall effectiveness is the area under the curve of effectiveness Ed,i versus compound
concentration Ci, between a null concentration and the last concentration C5, computed with
the trapezoidal rule. Since Ed,i may take negative values, εd is the area of the polygon lying
above the x axis minus the area of the polygon lying below.
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Plot of log(luminescence) versus exposure time for the MCF-7 cell line, using the
observations from the cells who were exposed to DMSO vehicle alone (N=56). The close
linear relationship suggests that the exponential growth model is a good representation of
cell population growth under HTS conditions. Thirteen of the 19 investigated cell lines
exhibited linear relationships between log(luminescence) and time, suggesting the adequacy
of the exponential growth model, at least for these cell lines and exposure times examined.
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Table 1
Description of Investigated Cell Lines. All Lines were Cancerous, Except the Normal MRC-5
Cell Line Tissue Description





HT-1376 Urinary bladder carcinoma, grade 3
HT-29 Colorectal-adenocarcinoma, epithelial
JMAR Oral cavity-squamous
Jurkat, E6-1 T lymphocyte-acute
LNCaP Prostate carcinoma
MCF-7 Breast-adenocarcinoma, epithelial
MDA-1986 Head and neck-squamous
MRC-5 Normal lung fibroblast
NCI-H226 Lung squamous cell carcinoma; mesothelioma
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Table 4
Summary of Correlation Coefficients R Between Observed and Predicted Log-Transformed Luminescence
Measures, where the Predictions were Computed with the Proposed Linear Regression Model. The Relatively
High Correlations Described in the Table Suggest that the Model Fit Dose-Response Data from HTS Toxicity
Screens Remarkably Well.a,b
Cell line Minimum of 26 Correlations Maximum of 26 Correlations Average of 26 Correlations
HCT-116 0.94 0.98 0.97
HT-1376c 0.84 0.91 0.88
Jurkatd 0.86 0.92 0.90
MRC-5e 0.59 0.83 0.65
DRO 0.86 0.98 0.97
PC3MM2 0.88 0.95 0.94
HCC827 0.77 0.95 0.93
MDA-1986 0.90 0.98 0.97
OVCAR3 0.66 0.76 0.69
NPA 0.91 0.95 0.93
LNCaP 0.93 0.99 0.99
A549 0.94 0.98 0.97
JMAR 0.91 0.97 0.95
MCF-7 0.93 0.96 0.95
NCI-H441 0.68 0.83 0.76
SK-BR-3f 0.82 0.91 0.86
Coav-3 0.53 0.85 0.60
HT-29 0.98 0.99 0.99
NCI-H226g 0.74 0.97 0.93
a
All correlations that are summarized in the table were significant. Each correlation corresponded to one investigated compound.
b
For all cell lines except HT-1376, Jurkat, MRC-5, SK-BR-3 and NCI-H226, each of the summarized correlations was computed with N=96
luminescence measures; 56 of these measures corresponded to DMSO alone, and the remaining measures to compound concentrations greater than
0. For the other cell lines, one time point from DMSO-alone data was excluded from computations and, therefore, 82 luminescence measures were
used to compute each correlation.
c
Luminescence measures obtained after 4 hours under DMSO alone were excluded from computations (see explanation in Model Fit Section).
d
Luminescence measures obtained after 24 hours under DMSO alone were excluded from computations.
e
Luminescence measures obtained after 72 hours under DMSO alone were excluded from computations.
f
Luminescence measures obtained after 4 hours under DMSO alone were excluded from computations.
g
Luminescence measures obtained after 48 hours under DMSO alone were excluded from computations.
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